1. Home
  2. CUE vs VTIX Comparison

CUE vs VTIX Comparison

Compare CUE & VTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$24.92

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo Virtuix Holdings Inc. Class A Common Stock

VTIX

Virtuix Holdings Inc. Class A Common Stock

N/A

Current Price

$2.80

Market Cap

109.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CUE
VTIX
Founded
2014
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
109.9M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CUE
VTIX
Price
$24.92
$2.80
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$120.00
N/A
AVG Volume (30 Days)
70.8K
227.9K
Earning Date
05-13-2026
08-11-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
N/A
EPS
N/A
N/A
Revenue
$27,466,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
195.75
N/A
52 Week Low
$0.17
$3.00
52 Week High
$41.42
$9.00

Technical Indicators

Market Signals
Indicator
CUE
VTIX
Relative Strength Index (RSI) 49.46 36.10
Support Level $23.16 N/A
Resistance Level $32.60 $4.51
Average True Range (ATR) 3.73 0.34
MACD -0.59 -0.01
Stochastic Oscillator 18.74 15.91

Price Performance

Historical Comparison
CUE
VTIX

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About VTIX Virtuix Holdings Inc. Class A Common Stock

Virtuix Holdings Inc develops technologies for immersive virtual environments, including both simulated and real-world applications. It develops virtual reality hardware and software, including the Omni Pro, an omni-directional treadmill designed to allow users to walk and run in multiple directions inside video games and other virtual worlds. The company operates at the intersection of gaming, fitness, and enterprise virtual reality. It has commercialized three products. The company operates in a single operating segment: the design, development, marketing, and sale of omni-directional treadmills, accessories, and related services to consumer and commercial customers. It derives revenue through a combination of hardware sales and recurring software and service income.

Share on Social Networks: